PT1041991E - Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla - Google Patents

Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla Download PDF

Info

Publication number
PT1041991E
PT1041991E PT98964764T PT98964764T PT1041991E PT 1041991 E PT1041991 E PT 1041991E PT 98964764 T PT98964764 T PT 98964764T PT 98964764 T PT98964764 T PT 98964764T PT 1041991 E PT1041991 E PT 1041991E
Authority
PT
Portugal
Prior art keywords
tetracyclins
treatment
multiple sclerosis
tnfalpha
chemically modified
Prior art date
Application number
PT98964764T
Other languages
English (en)
Inventor
Ashok Amin
Steven Abramson
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of PT1041991E publication Critical patent/PT1041991E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT98964764T 1997-12-19 1998-12-17 Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla PT1041991E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6826897P 1997-12-19 1997-12-19
PCT/US1998/026870 WO1999030720A1 (en) 1997-12-19 1998-12-17 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha

Publications (1)

Publication Number Publication Date
PT1041991E true PT1041991E (pt) 2008-10-03

Family

ID=22081491

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98964764T PT1041991E (pt) 1997-12-19 1998-12-17 Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla

Country Status (11)

Country Link
US (1) US6319910B1 (pt)
EP (1) EP1041991B1 (pt)
JP (1) JP4733266B2 (pt)
AT (1) ATE399013T1 (pt)
AU (1) AU2001599A (pt)
CA (1) CA2316972C (pt)
DE (1) DE69839649D1 (pt)
DK (1) DK1041991T3 (pt)
ES (1) ES2310018T3 (pt)
PT (1) PT1041991E (pt)
WO (1) WO1999030720A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7906481B2 (en) * 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
CA2396593A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
CA2444899C (en) * 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2332548A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
KR101025400B1 (ko) * 2002-03-21 2011-03-28 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
WO2004038000A2 (en) * 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
EP2277504A1 (en) * 2002-10-24 2011-01-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
WO2006036655A2 (en) * 2004-09-22 2006-04-06 Research Foundation Of State University Of New York Use of low dose chemically modified tetracyclines to reduce inflammatory mediators
GB0518558D0 (en) * 2005-09-12 2005-10-19 Givaudan Sa Improvements in or related to organic compounds
WO2007098099A2 (en) * 2006-02-16 2007-08-30 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
JPH0454160A (ja) * 1990-06-21 1992-02-21 Kuraray Co Ltd テトラサイクリン誘導体
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
JPH04178359A (ja) * 1990-07-01 1992-06-25 Kuraray Co Ltd テトラサイクリン誘導体
US5223248A (en) 1991-02-11 1993-06-29 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing antiplaque properties
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
DK0599397T3 (da) * 1992-11-17 1996-09-16 Univ New York State Res Found Tetracycliner, herunder non-mikrobielle, kemisk-modificerede tetracycliner, inhiberer overdreven collagentværbinding ved diabetes
JPH0782153A (ja) * 1993-07-20 1995-03-28 Sumio Arai エンドトキシン中和剤
JP2676093B2 (ja) * 1994-12-05 1997-11-12 ザ リサーチ ファンデーション オブ ステート ユニバーシティ オブ ニューヨーク 動物飼料組成物
JPH08268907A (ja) * 1995-03-31 1996-10-15 Sunstar Inc 歯周組織再生促進剤
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
WO1999030720A9 (en) 1999-10-07
CA2316972A1 (en) 1999-06-24
AU2001599A (en) 1999-07-05
EP1041991B1 (en) 2008-06-25
WO1999030720A8 (en) 1999-09-02
JP4733266B2 (ja) 2011-07-27
WO1999030720A1 (en) 1999-06-24
JP2002508327A (ja) 2002-03-19
ES2310018T3 (es) 2008-12-16
CA2316972C (en) 2009-02-24
DK1041991T3 (da) 2008-07-28
US6319910B1 (en) 2001-11-20
EP1041991A1 (en) 2000-10-11
ATE399013T1 (de) 2008-07-15
EP1041991A4 (en) 2002-08-21
DE69839649D1 (de) 2008-08-07

Similar Documents

Publication Publication Date Title
PT1041991E (pt) Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
WO2002098898A3 (en) FLJs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003005971A3 (en) Tetracycline compounds having target therapeutic activities
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
WO2002099060A3 (en) Dgks as modifiers of the p53 pathway and methods of use
NO974824D0 (no) Arteriovenöse og venös transplantasjonsbehandlinger, fremgangsmåter og blandinger
CY1108110T1 (el) Παραγοντες και μεθοδοι για προστασια, θεραπεια και επιδιορθωση συνδετικου ιστου
BR9916544A (pt) Processo para tratamento de neoplasia em um indivìduo que necessita de tal tratamento, e, combinação
BR0114344A (pt) Retinóides para o tratamento de enfisema
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
WO2003045321A3 (en) MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
ES2103871T3 (es) Medicamento para oftalmologia y su empleo.
CY1108310T1 (el) Μη αντιβακτηριδιακες τετρακυκλινες για την αγωγη της σκληρυνσεως κατα πλακας
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
NO20032799D0 (no) Nye terapeutiske anvendelser av tienylsykloheksylamin- derivater
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
ES2150848A1 (es) Heterociclos metiloxinaftil sustituidos con accion antagonista de los leucotrienos.
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита
SG153654A1 (en) Replikin peptides and uses thereof
GEP20012408B (en) Means for Treatment of Psoriasis